Absolutely. As I mentioned, we represent the whole spectrum, but of our 130 members, I'd say over 100 would be considered small to medium-sized enterprises.
I think the biggest area in which it causes issues is the one I talked about, involving the system for Canada's plants with novel traits. Even if you're not using biotechnology or GMO or whatever you want to call it—we represent organic, conventional, and biotech, all three—even conventionally bred plants, as Ray was speaking to, can be subject to Canada's plants with novel traits system.
What we've seen is that some companies that don't have regulatory affairs teams based in Ottawa.... Our largest companies certainly do, here in Ottawa, or they are based out of Calgary. When they're doing their own innovation in-house, they set their own parameters. They innovate to a certain level, because they feel that if they innovate above that level, they're going to be subject to a pre-assessment from the CFIA and Health Canada.
They often come to us or our partners at CropLife Canada. What we've actually seen of late is that our small or medium-sized companies are actually going to our large multinationals to get their feedback on whether they feel they would be regulated.
The biggest thing is a clear path to market so that a company that employs 12 in Morden, Manitoba, can know what the requirement is to bring a new variety forward.